Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2

被引：81
|
作者：
Sapkal, Gajanan N. [1 ]
Yadav, Pragya D. [1 ]
Ella, Raches [2 ]
Deshpande, Gururaj R. [1 ]
Sahay, Rima R. [1 ]
Gupta, Nivedita [3 ]
Vadrevu, Krishna Mohan [2 ]
Abraham, Priya [1 ]
Panda, Samiran [3 ]
Bhargava, Balram [3 ]
机构：
[1] Indian Council Med Res, Natl Inst Virol, Pune 411021, Maharashtra, India
[2] Bharat Biotech Int Ltd, Genome Valley, Hyderabad 500078, Telangana, India
[3] Indian Council Med Res, V Ramalingaswami Bhawan, POB 4911, New Delhi 110029, India
来源：
JOURNAL OF TRAVEL MEDICINE | 2021年 / 28卷 / 04期
关键词：
SARS-CoV-2; N501Y; escape mutants; vaccine efficacy; neutralization; variant of concern;
D O I：
10.1093/jtm/taab051
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
[No abstract available]
引用
收藏
页数：3
相关论文
共 37 条
  • [31] Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines
    Hvidt, Astrid K. K.
    Baerends, Eva A. M.
    Sogaard, Ole S. S.
    Staerke, Nina B. B.
    Raben, Dorthe
    Reekie, Joanne
    Nielsen, Henrik
    Johansen, Isik S. S.
    Wiese, Lothar
    Benfield, Thomas L. L.
    Iversen, Kasper K. K.
    Mustafa, Ahmed B. B.
    Juhl, Maria R. R.
    Petersen, Kristine T. T.
    Ostrowski, Sisse R. R.
    Lindvig, Susan O. O.
    Rasmussen, Line D. D.
    Schleimann, Marianne H. H.
    Andersen, Sidsel D. D.
    Juhl, Anna K. K.
    Dietz, Lisa L. L.
    Andreasen, Signe R. R.
    Lundgren, Jens
    Ostergaard, Lars
    Tolstrup, Martin
    FRONTIERS IN MEDICINE, 2022, 9
  • [32] Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate
    Chen, Wen-Hsiang
    Pollet, Jeroen
    Strych, Ulrich
    Lee, Jungsoon
    Liu, Zhuyun
    Kundu, Rakhi Tyagi
    Versteeg, Leroy
    Villar, Maria Jose
    Adhikari, Rakesh
    Wei, Junfei
    Poveda, Cristina
    Keegan, Brian
    Bailey, Aaron Oakley
    Chen, Yi-Lin
    Gillespie, Portia M.
    Kimata, Jason T.
    Zhan, Bin
    Hotez, Peter J.
    Bottazzi, Maria Elena
    PROTEIN EXPRESSION AND PURIFICATION, 2022, 190
  • [33] Immune responses against different variants of SARS-CoV-2 including Omicron following 6 months of administration of heterologous prime-boost COVID-19 vaccine
    Sapkal, Gajanan
    Srivastava, Rajni Kant
    Dwivedi, Gaurav
    Sahay, Rima R.
    Yadav, Pragya D.
    Deshpande, Gururaj R.
    Singh, Rajeev
    Nyayanit, Dimpal A.
    Patil, Deepak Y.
    Shete-Aich, Anita M.
    Zaman, Kamran
    Chaudhari, Anil K.
    Gupta, Nivedita
    Panda, Samiran
    Abraham, Priya
    Bhargava, Balram
    JOURNAL OF TRAVEL MEDICINE, 2022, 29 (03)
  • [34] Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination
    Chen, Lin-Lei
    Lu, Lu
    Choi, Charlotte Yee-Ki
    Cai, Jian-Piao
    Tsoi, Hoi-Wah
    Chu, Allen Wing-Ho
    Ip, Jonathan Daniel
    Chan, Wan-Mui
    Zhang, Ricky Ruiqi
    Zhang, Xiaojuan
    Tam, Anthony Raymond
    Lau, Daphne Pui-Ling
    To, Wing-Kin
    Que, Tak-Lun
    Yip, Cyril Chik-Yan
    Chan, Kwok-Hung
    Cheng, Vincent Chi-Chung
    Yuen, Kwok-Yung
    Hung, Ivan Fan-Ngai
    To, Kelvin Kai-Wang
    CLINICAL INFECTIOUS DISEASES, 2022, 74 (09) : 1623 - 1630
  • [35] A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial
    Thiem, Vu Dinh
    Anh, Pham Thi Van
    Van Men, Chu
    Hung, Do Thai
    Pollard, Andrew J.
    Kamitani, Akari
    Tada, Yukio
    Fukuyama, Hidenori
    Iwasaki, Yuka
    Ariyasu, Mari
    Sonoyama, Takuhiro
    VACCINE, 2024, 42 (17) : 3699 - 3709
  • [36] A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses
    Wilkinson, Bethanie
    Patel, Kinjal S.
    Smith, Katherine
    Walker, Robert
    Wang, Chengbin
    Greene, Ann M.
    Smith, Gale
    Smith, Emily R.
    Gurwith, Marc
    Chen, Robert T.
    VACCINE, 2023, 41 (45) : 6762 - 6773
  • [37] STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease
    Woelfel, Simon
    Junker, Daniel
    Bergamin, Irina
    Meyer-Herbon, Pamela
    Stillhard, Roman
    Graf, Nicole
    Leinenkugel, Georg
    Dutschler, Joel
    Koenig, Marius
    Kammerlander, Livia
    Hauptle, Rahel
    Zwyssig, Sarah
    Krieger, Claudia
    Truniger, Samuel
    Koller, Seraina
    Metzger-Peter, Katline
    Frei, Nicola
    Albrich, Werner C.
    Friedrich, Matthias
    Bernsmeier, Christine
    Niess, Jan Hendrik
    Korte, Wolfgang
    Burgi, Justus J.
    Dulovic, Alex
    Schneiderhan-Marra, Nicole
    Semela, David
    Brand, Stephan
    VACCINES, 2024, 12 (11)
1234